VTRS vs. BGNE, TEVA, KRTX, RDY, UTHR, SRPT, CTLT, BMRN, ALNY, and ROIV
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include BeiGene (BGNE), Teva Pharmaceutical Industries (TEVA), Karuna Therapeutics (KRTX), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Catalent (CTLT), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
BeiGene received 517 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 69.06% of users gave BeiGene an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Viatris currently has a consensus price target of $11.00, indicating a potential downside of 3.17%. BeiGene has a consensus price target of $251.70, indicating a potential upside of 74.22%. Given BeiGene's stronger consensus rating and higher possible upside, analysts plainly believe BeiGene is more favorable than Viatris.
Viatris has a net margin of 0.35% compared to BeiGene's net margin of -35.86%. Viatris' return on equity of 17.03% beat BeiGene's return on equity.
Viatris has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
In the previous week, BeiGene had 7 more articles in the media than Viatris. MarketBeat recorded 8 mentions for BeiGene and 1 mentions for Viatris. Viatris' average media sentiment score of 1.20 beat BeiGene's score of 0.36 indicating that Viatris is being referred to more favorably in the media.
79.9% of Viatris shares are held by institutional investors. Comparatively, 48.6% of BeiGene shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 7.4% of BeiGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Viatris has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
Summary
Viatris beats BeiGene on 10 of the 18 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
